We retrospectively analyzed 35 patients with del17p or TP53mut AML treated with venetoclax + HMA or HMA alone….The composite complete remission (CCR) rate significantly favored the venetoclax arm at 40.0% (95% CI, 21.9 - 61.3), compared to 0% (95% CI, 0 - 27.8) in the monotherapy arm (p = 0.029). Furthermore, the median overall survival significantly favored the venetoclax cohort at 6.0 months compared to 3.4 months in the HMA cohort (p = 0.026)....The addition of venetoclax offers significantly superior response and survival compared to HMA monotherapy in patients with del17p or TP53mut AML.